India vs Northern Africa and Western Asia: Percentage of bloodstream infection due to Escherichia coli resistant
India
77.5%
in 2022
Northern Africa and Western Asia
52.4%
in 2022
India rank
4th
Northern Africa and Western Asia rank
7th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- India
- Northern Africa and Western Asia
How they compare
India currently reports 77.5% against 52.4% in Northern Africa and Western Asia, a difference of 25.1%.
That makes India's figure about 1.5 times Northern Africa and Western Asia's.
Across all 6 years both countries report, India has been ahead every year.
India ranks 4th and Northern Africa and Western Asia ranks 7th of 50 countries.
India has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | India | Northern Africa and Western Asia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 78.2% | 52.0% | 26.2% | India |
| 2020s | 80.6% | 53.7% | 27.0% | India |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, India or Northern Africa and Western Asia?
- India, at 77.5% against 52.4% in Northern Africa and Western Asia as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between India and Northern Africa and Western Asia?
- 25.1%, with India ahead.
- How many years of comparable data are there for India and Northern Africa and Western Asia?
- 6 years are reported by both, from 2017 to 2022.
- How do India and Northern Africa and Western Asia rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- India ranks 4th and Northern Africa and Western Asia ranks 7th of 50 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.